Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.

Products

Sobi has a diversified and growth-oriented commercial product portfolio within three business lines.
To products

Transparency

Sobi supports transparency initiatives, including the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code in Europe and the Physician Payments Sunshine Act in the United States (Sunshine Act).
Read more

Annual General Meeting 2016

The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, was held on Tuesday, May 24, 2016 at 3.00 p.m. at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.
Read more

Presentation of Sobi's Interim Report January - June 2016

15 July, 2016 - Revenues for the quarter totalled SEK 1,469 M (764), an increase of 92 per cent.

Share Price

SEK105.40

Volume: 732,985
Ticker: SOBI
List:
SSE Large

Opouštíte webové stránky SOBI

Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.

Přejete si opustit stránky?

Ano    Ne